Polymer adjuvant
AssigneesOxford University Innovation Limited, The United States of America, as represented by the Secretary, Department of Health and Human Servic
InventorsKerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
Life of this patent
Estimating the term…
Abstract
The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
Claims34
An adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to linear or branched unimolecular polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli.
The adjuvant according to any receding claim, wherein the particles are a size capable of being phagocytosed, or larger.
The adjuvant according to any preceding claim, wherein the adjuvant is capable of assembling into particles of sizes between about 20 nm and about 10,000 nm.
The adjuvant according to any preceding claim, wherein the adjuvant is for local administration to a specific tissue, site, or region of the body.
The adjuvant according to any preceding claim, wherein the adjuvant is capable of being substantially retained in the body at the site of administration.
The adjuvant according to any preceding claim, wherein the adjuvant is capable of forming particles at the site of radiation or inflammation.
The adjuvant according to any preceding claim, wherein the polymer comprises or consists of monomers of any of the group selected from N-isopropylacrylamide (NIPAM);
- N-isopropylmethacrylamide (NIPMAM);
- N,N′-diethylacrylamide (DEAAM);
- N-(L)-(1-hydroxymethyl) propyl methacrylamide (HMPMA);
- N,N′-dimethylethylmethacrylate (DMEMA), 2-(2-methoxyethoxy)ethyl methacrylate (DEGMA);
- pluronic, PLGA and poly(caprolactone);
- or combinations thereof.
The adjuvant according to any preceding claim, wherein the polymer comprises or consists of block-copolymer or graft-copolymer.
The adjuvant according to any preceding claim, wherein the Pattern Recognition Receptor (PRR) agonist comprises a PAMP (pathogen-associated molecular pattern).
The adjuvant according to any preceding claim, wherein the PRR agonist comprises a TLR agonist, a NOD-like receptor (NLR) agonist, C-type lectin receptor (CLRs), or agonists of STING.
The adjuvant according to any preceding claim, further comprising an antigen linked to the polymer or co-formulated with the polymer.
The adjuvant according to any preceding claim, wherein the PRR agonist molecules and/or antigens are linked to the monomer units distributed along the polymer backbone at a density of between about 1 mol % and about 100 mol %
The adjuvant according to any preceding claim, wherein the PRR agonist molecules and/or antigens are linked to the monomer units distributed along the polymer backbone at a density of between about 5 mol % and about 20 mol %.
The adjuvant according to any preceding claim, wherein the PRR agonist and/or antigen are covalently linked to the polymer.
The adjuvant according to any preceding claim, wherein the PRR agonist and/or antigen are linked to the polymer by a linker molecule.
An immunogenic composition comprising an adjuvant and an antigen according to any preceding claim.
A method of treatment or prevention of a disease comprising the administration of an adjuvant or immunogenic composition according to any preceding claim to a subject in need thereof.
An adjuvant, immunogenic composition, vaccine, use or method substantially described herein, and optionally with reference to the accompanying figures.
Dependencies are inferred from the claim text.